Published in AIDS Res Hum Retroviruses on September 01, 2012
Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev (2013) 0.83
Absence of effect of menopause status at initiation of first-line antiretroviral therapy on immunologic or virologic responses: a cohort study from Rio de Janeiro, Brazil. PLoS One (2014) 0.77
Immunological and Clinical Responses following the Use of Antiretroviral Therapy among Elderly HIV-Infected Individuals Attending Care and Treatment Clinic in Northwestern Tanzania: A Retrospective Cohort Study. J Sex Transm Dis (2016) 0.76
Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection. Medicine (Baltimore) (2016) 0.75
Self-rated health and substance use among individuals in HIV care in Rio de Janeiro, Brazil: a cross-sectional study. Int J STD AIDS (2017) 0.75
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr (2006) 12.07
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis (2008) 4.46
HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (2009) 4.19
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis (2010) 3.79
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis (2005) 3.57
Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis (2006) 2.72
Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol (2007) 2.62
Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med (2005) 2.38
HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS (2010) 2.28
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11
Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med (2007) 2.07
AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med (1994) 1.94
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS (2003) 1.77
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS (2004) 1.67
Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr (2008) 1.49
[HIV infection in different age groups: Potential implications for prevention. CoRIS Cohort, Spain, 2004-2008]. Med Clin (Barc) (2010) 1.40
Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr (2006) 1.35
Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS (2008) 1.34
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS One (2006) 1.32
The aging of the HIV epidemic. Curr HIV/AIDS Rep (2008) 1.27
The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology (2009) 1.26
Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med (2006) 1.24
Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis (2006) 1.23
Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS (2001) 1.23
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis (2004) 1.18
Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res (2008) 1.17
Greater effect of highly active antiretroviral therapy on survival in people aged > or =50 years compared with younger people in an urban observational cohort. Clin Infect Dis (2003) 1.12
A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS (2000) 1.10
Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years. Clin Infect Dis (2007) 1.09
Ageing with HIV: newly diagnosed older adults in Italy. AIDS Care (2008) 1.09
Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. AIDS Res Hum Retroviruses (2010) 1.07
European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS (2003) 1.05
HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect (2008) 1.04
Older age and plasma viral load in HIV-1 infection. AIDS (2004) 1.04
Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis (2002) 1.01
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis (2005) 1.00
Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr (2003) 0.99
The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med (2008) 0.99
[Evolution of a cohort of patients over 60 years old with HIV infection treated with highly-active antiretroviral therapy]. Enferm Infecc Microbiol Clin (2005) 0.77
[Clinical and epidemiological study of a series of HIV-infected patients over 50 years old]. Enferm Infecc Microbiol Clin (2005) 0.76
[AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. Enferm Infecc Microbiol Clin (2010) 0.76
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Double-blind clinical trial to compare autologous fat grafts versus autologous fat grafts with PDGF: no effect of PDGF. Plast Reconstr Surg (2014) 3.21
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS (2008) 2.92
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Rhabdomyolysis of infectious and noninfectious causes. South Med J (2002) 2.40
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr (2009) 2.14
Improved prognosis after using mild hypothermia to treat cardiorespiratory arrest due to a cardiac cause: comparison with a control group. Rev Esp Cardiol (2009) 2.13
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother (2005) 2.10
[The multiple faces of the control of tuberculosis]. Enferm Infecc Microbiol Clin (2003) 1.95
[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]. Enferm Infecc Microbiol Clin (2011) 1.92
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med (2010) 1.89
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol (2006) 1.88
[Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results]. Enferm Infecc Microbiol Clin (2007) 1.83
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS (2009) 1.81
Adverse outcomes associated with stimulator-based peripheral nerve blocks with versus without ultrasound visualization. Reg Anesth Pain Med (2009) 1.68
[Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Arch Bronconeumol (2010) 1.67
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS (2011) 1.65
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology (2009) 1.64
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol (2009) 1.61
The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS (2006) 1.60
Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol (2005) 1.58
[HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)]. Enferm Infecc Microbiol Clin (2009) 1.57
Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS (2003) 1.55
Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms. AIDS (2012) 1.55
Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med (2002) 1.51
Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr (2007) 1.51
Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia. Liver Transpl (2011) 1.50
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clin Infect Dis (2011) 1.50
Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl (2002) 1.50
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr (2009) 1.49
Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother (2003) 1.48
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS (2012) 1.46
[Consensus document on the diagnosis, treatment and prevention of tuberculosis]. Enferm Infecc Microbiol Clin (2010) 1.44
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS (2004) 1.44
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr (2007) 1.43
[Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm Infecc Microbiol Clin (2004) 1.42
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr (2005) 1.41
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. J Infect (2011) 1.39
Changes in the epidemiology of tuberculosis: the influence of international migration flows. Enferm Infecc Microbiol Clin (2011) 1.39
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS (2010) 1.39
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS One (2011) 1.38
Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses (2012) 1.36
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol (2008) 1.35
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. PLoS One (2006) 1.32
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS (2006) 1.30
Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res (2009) 1.30
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill (2015) 1.29
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr (2015) 1.28
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses (2007) 1.26
Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses (2006) 1.26
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS (2013) 1.26
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis (2012) 1.25
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res (2010) 1.25
Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS (2010) 1.24
The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect (2012) 1.24
Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis (2003) 1.24
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One (2011) 1.24
Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother (2007) 1.23
Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother (2009) 1.23
Primary angioplasty reduces the risk of left ventricular free wall rupture compared with thrombolysis in patients with acute myocardial infarction. J Am Coll Cardiol (2002) 1.22
Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size. Am Heart J (2005) 1.22
Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis (2003) 1.21